Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sarmad Sadeghi
City of Hope Comprehensive Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University Health Network Princess Margaret Cancer Center P2c
Toronto, Ontario, Canada
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Los Angeles County-Usc Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Keck Medical Center of Usc Pasadena
Pasadena, California, United States
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- University of Colorado Hospital
Aurora, Colorado, United States
- Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
- Moffitt Cancer Center P2c
Tampa, Florida, United States
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- Uc Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois, United States
- Mayo Clinic Cancer Center P2c
Rochester, Minnesota, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Case Western Reserve University
Cleveland, Ohio, United States
- Cleveland Clinic Foundation
Cleveland, Ohio, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
- University of Texas M D Anderson Cancer Center P2c
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Dec 2014
- Primary completion
- 18 Mar 2019
- Completion
- 11 Jul 2019
- Last update posted
- 16 Dec 2019
- Registered enrollment
- 26
- Registry id
- NCT02178241
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.